Biosynex SA
PAR:ALBIO

Watchlist Manager
Biosynex SA Logo
Biosynex SA
PAR:ALBIO
Watchlist
Price: 2.77 EUR -3.82% Market Closed
Market Cap: 29.8m EUR
Have any thoughts about
Biosynex SA?
Write Note

Biosynex SA
Accrued Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Biosynex SA
Accrued Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accrued Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Biosynex SA
PAR:ALBIO
Accrued Liabilities
€10.2m
CAGR 3-Years
-28%
CAGR 5-Years
51%
CAGR 10-Years
48%
Edap Tms SA
NASDAQ:EDAP
Accrued Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Biomerieux SA
PAR:BIM
Accrued Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Carmat SA
PAR:ALCAR
Accrued Liabilities
€7.1m
CAGR 3-Years
19%
CAGR 5-Years
22%
CAGR 10-Years
19%
Visiomed Group SA
PAR:ALVMG
Accrued Liabilities
€827k
CAGR 3-Years
-38%
CAGR 5-Years
-29%
CAGR 10-Years
-4%
Amplitude Surgical SA
PAR:AMPLI
Accrued Liabilities
€9.9m
CAGR 3-Years
4%
CAGR 5-Years
1%
CAGR 10-Years
N/A
No Stocks Found

Biosynex SA
Glance View

Market Cap
28.9m EUR
Industry
Health Care

Biosynex SA engages in the development, production, and distribution of Rapid Diagnostics Tests (RDTs) for pathologies. The company is headquartered in Illkirch-Graffenstaden, Grand Est. The company went IPO on 2011-03-21. The Company’s products are used by biological and analytical services laboratories, obstetric units and emergency units, as well as in medical resource-limited settings. Biosynex SA specializes in four fields: tropical diseases, emergency markers, infectious diseases and autoimmunity. The Company’s products include Amnioquick (Obstetrics); Immunoquick Malaria Falciparum and Immunoquick Malaria +4 (Parasitology); Immunoquick Elifa HSV IGG, Immunoquick Elifa EBV G and Immunoquick Mono (Virology); Immunoquick Filtration CELIAC IgA and Immunoquick TG (Autoimmunology); and Immunoquick Tetanus (Bacteriology). The company operates through Fumouze Diagnostics and SR2B.

ALBIO Intrinsic Value
7.73 EUR
Undervaluation 64%
Intrinsic Value
Price

See Also

What is Biosynex SA's Accrued Liabilities?
Accrued Liabilities
10.2m EUR

Based on the financial report for Jun 30, 2024, Biosynex SA's Accrued Liabilities amounts to 10.2m EUR.

What is Biosynex SA's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 10Y
48%

Over the last year, the Accrued Liabilities growth was -15%. The average annual Accrued Liabilities growth rates for Biosynex SA have been -28% over the past three years , 51% over the past five years , and 48% over the past ten years .

Back to Top